Molecular imaging: The vision and opportunity for radiology in the future

Radiology

Volumn 244, Issue 1, 2007, Pages 39-47

  Hoffman, John M ^a   Gambhir, Sanjiv S ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 131; PENTETREOTIDE; PENTETREOTIDE IN 111;

CANCER; CANCER DIAGNOSIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MODEL; EARLY DIAGNOSIS; ECHOGRAPHY; FUNDING; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; IMAGING SYSTEM; MEDICAL RESEARCH; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGY; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; CONTRAST MEDIA; DIAGNOSTIC IMAGING; FINANCING, GOVERNMENT; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; RADIOLOGY; RADIOPHARMACEUTICALS; RESEARCH SUPPORT;

EID: 34250849756     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2441060773     Document Type: Review

References (73)

1. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-333.
2. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17:545-580.
3. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11(8):2785-2808.
4. Hicks RJ. The role of PET in monitoring therapy. Cancer Imaging 2005;5(1):51-57.
5. The market for PET radiopharmaceuticals & PET imaging. Bio-Tech report no. 200. BioTech Systems Web site. http://biotechsystems.com/reports/200/ default.asp. Accessed April 9, 2006.
6. Warburg O. The metabolism of tumors. New York, NY: Richard R. Smith, 1931; 1-129.
7. Weber G. Enzymology of cancer cells. II. N Engl J Med 1977;296(10):541-551.
8. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (E-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6(5):371-388.
9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the EDG PET literature. J Nucl Med 2001;42(5 suppl):1S-93S.
10. Jaffer EA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005;293(7):855-862.
11. Jager PL, de Korte MA, Lub-de Hooge MN, et al. Molecular imaging: what can be used today. Cancer Imaging 2003:5(spec no. A):S27-S32.
12. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther 2005;3(4):705-715.
13. Pomper MG. Translational molecular imaging for cancer. Cancer Imaging 2005;5(spec no. A):S16-S26.
14. Landini L, Santarelli ME, Positano V, Leone A. Molecular imaging: its application in cardiovascular diagnosis. Curr Pharm Des 2005;11(17):2225-2234.
15. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent, and fluorescent optical imaging in cancer research. Mol Imaging 2003;2(4):303-312.
16. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2(9):083-693.
17. Hillman BJ, Neiman HI. Translating molecular imaging research into radiologic practice: summary of the proceedings of the American College of Radiology Colloquium, April 22-24, 2001. Radiology 2002;222:19-24.
18. Pomper MG. Molecular imaging: an overview. Acad Radiol 2001;8:1141-1153.
19. Luker GD, Piwnica-Worms D. Beyond the genome: molecular imaging in vivo with PET and SPECT. Acad Radiol 2001;8:4-14.
20. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11(22):7967-7985.
21. Wagenaar DJ, Weissleder R, Arne Hengerer A. Glossary of molecular imaging terminology. Acad Radiol 2001;8:409-420.
22. Wang J, Maurer L. Positron emission tomography: applications in drug discovery arrd drug development. Curr Top Med Chem 2005;5(11):1053-1075.
23. Eckelman WC, Rohatagi S, Krohn KA, Vera DR. Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic? Nucl Med Biol 2005;32(7):657-662.
24. Rudin M. Molecular imaging: basic principles and applications in biomedical research. London, England: Imperial College Press, 2005;
25. Rudin M, Rausch M, Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol Imaging Biol 2005;7(1):5-13.
26. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-131.
27. Therasse P, Arbuck SG, Eisenbauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
28. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921. hilp://www.genome.gov/11006929. Published April 14, 2003; Accessed April 2, 2006.
29. Mouse Genome Sequencing Consortium; Waterston RH, Lindblad-Toh K, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-562. http://www.nature.com/nature/journal/v420/n6915/full/ nature01262fs.html. Published December 5, 2002. Accessed April 15, 2006.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
31. Extraordinary opportunities for new investments. In: The nation's investment in cancer research: a budget proposal for fiscal years 1997/98. Bypass budget. National Cancer Institute, Financial Management Branch Web site. http://fmb.cancer.gov/financial/bypass.htm. Accessed July 15, 2006.
32. Extraordinary opportunities for investment. In: The nation's investment in cancer research: a budget proposal for fiscal year 1999. Bypass budget. National Cancer Institute, Einancial Management Branch Web site. http://fmb.cancer.gov/financial/attachments/bypass_1999.pdf. Accessed July 15, 2006.
33. Extraordinary opportunities for investment. In: The nation's investment in cancer research: a budget proposal for fiscal year 2000. Bypass budget. National Cancer Institute, Financial Management Branch Web site. http://fmb.cancer.gov/financial/attachments/bypass_2000.pdf. Accessed July 15, 2006.
34. Scientific priorities for cancer research: NCI's extraordinary opportunities. In: The nation's investment in cancer research: a budget proposal for fiscal year 2001. Bypass budget. National Cancer Institute, Einancial Management Branch Web site. http://fmb.cancer.gov/financial/attachmenls/ bypass_2001.pdf. Accessed July 15, 2006.
35. Hoffman JM. Imaging in cancer: a National Cancer Institute "extraordinary opportunity". Neoplasia 2000;2(1-2):5-8.
36. Hoffman JM, Menkens A. Molecular imaging in cancer: future directions and goals of the National Cancer Institute. Acad Radiol 2000;7(10):905-907.
37. In vivo cancer molecular imaging centers (ICMICs). National Cancer Institute, Cancer Imaging Program Web site. hltp://imaging.cancer.gov/ programsandresources/specializedinitiatives/icmics. Accessed April 15, 2006.
38. Small animal imaging resource program (SAIRP). National Cancer Institute, Cancer Imaging Program Web site. http://imaging.cancer.gov/ programsandresources/specializedinitiatives/SAIRP. Accessed April 15, 2006.
39. Croft BY, Hoffman JM. NCI-funded small animal imaging programs. National Cancer Institute. Acad Radiol 2001;8:372-374.
40. Hoffman JM, Croft B. Future directions in small animal imaging. Lab Animal 2001;30(3):32-35.
41. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development: recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia. Clin Cancer Res 2002;8:314-346.
42. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000;78:199-334.
43. Development of clinical imaging drugs & enhancers (DCIDE). National Cancer Institute, Cancer Imaging Program Web site. http://imaging, cancer.gov/programsandresources/specializedinitiatives/dcide. Accessed April 14,2006.
44. Network for Iranslational research: optical imaging (NTROI). National Cancer Institute, Cancer Imaging Program Web site. http://imaging.cancer.gov/ programsandresources /specializedinitiatives/ntroi. Accessed April 14, 2006.
45. Overview of the NIH roadmap. NIH roadmap for medical research. Office of Portfolio Analysis and Strategic Initiatives, National Institutes of Health Web site. http://nihroadmap.nib.gov/ovevview.asp. Accessed April 14, 2006.
46. NIH roadmap. NIH roadmap for medical research. Office of Portfolio Analysis and Strategic Initiatives, National Institutes of Health Web site. http://nihroadmap.nih.gov/. Accessed July 14, 2006.
47. Zerhouni E. Medicine. The NIH roadmap. Science 2003;302(5642):63-72.
48. Zerhouni EA. US biomedical research: basic, translational, and clinical sciences. JAMA 2005;294(11):1352-1358.
49. Molecular imaging & contrast agent database. MICAD NIH Roadmap, National Institutes of Health. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?caIl= bv.View.ShowTOC&rid=micad.TOC&depth?pi26〉2. Accessed April 14, 2006.
50. NIH roadmap initiatives. NIH roadmap for medical research. Office of Portfolio Analysis and Strategic Initiatives, National Institutes of Health. http://nihroadmap.nih.gov/initiatives .asp. Accessed April 14, 2006.
51. Center for molecular imaging research. Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard University Web site. http://www.mgh-cmir.org/. Accessed April 15, 2006.
52. Molecular imaging program al Stanford (MIPS). Molecular Imaging Program, Stanford University Weh site, http://mips.stanford.edu/. Accessed April 14, 2006.
53. Background on the Center for Advanced Biomedical Imaging Research. News backgrounders. The University of Texas MD Anderson Cancer Center Web site. hltp://www.mdanderson.org/departments/newsroom/display.cfm?id= ffd8860c-7f0c-49c5-b7ff27d9deecdc45&method=displayfull&pn= 7816f628-61d7-4b3c-88e76eac5072a6fe. Accessed April 15, 2006.
54. Integrated science, innovative technology: this is the Crump institute. Crump Institute for Molecular Imaging Weh site. http://www.crump.ucla.edu/. Accessed April 15, 2006.
55. The Society for Molecular Imaging Web site. http://www.molecularimaging. org/. Accessed April 15, 2006.
56. Academy of Molecular Imaging Web site. http://www.ami-imaging.org/public/ journal.htm. Accessed April 15, 2006.
57. Molecular Imaging Web site. http://www.journalsoft.com/molecularimaging/ journal/index.php. Accessed April 15, 2006.
58. Molecular Imaging and Biology Web site. http://www.ami-imaging.org/ public/journal.htm. Accessed April 15, 2006.
59. European Journal of Nuclear Medicine and Molecular Imaging Web site. http://www.springer.com/sgw/cda/frontpage/0,11855,4-0-70-1038116- detailsPage%253Djournal%257Cdescription%257Cdescription,00.html?referer=www. springer.com%2Fjournal%2F00259%2Fabout. Accessed April 15, 2006.
60. Society of Nuclear Medicine Weh site. http://interactive.snm.org/. Accessed April 15, 2006. The Journal of Nuclear Medicine Web site. http://jnm.snmjournals.org/. Accessed April 15, 2006.
61. Radiology Web site http://radiology.rsnajnls.org/. Accessed April 15, 2006.
62. Molecular Imaging Central Web site. http://www.mi-central.org/. Accessed April 15, 2006.
63. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-378.
64. Blasberg RG. Molecular imaging and cancer. Mol Cancer Ther 2003;2(3):335-343.
65. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;(suppl):96S-103S.
66. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Imaging gene expression: principles and assays. J Nucl Cardiol 1999;6(2):219-233.
67. Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 2002;16(4):336-351.
68. Blasberg R. Imaging gene expression and endogenous molecular processes: molecular imaging. J Cereb Blood Flow Metab 2002;22(10):1157-1164.
69. Luker GD, Sharma V, Pica CM, et al. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A 2002;99:6961-6966.
70. Luker GD, Sharma V, Piwnica-Worms D. Visualizing protein-protein interactions in living animals. Methods 2003;29(1):110-122.
71. Panhnurugan R, Massoud TF, Huang J, Gambhir SS. Molecular imaging of drug-modulated protein-protein interactions in living subjects. Cancer Res 2004;64(6):2113-2119.
72. Paulmurugan R, Umezawa Y, Gambhir SS. Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci U S A 2002;99(24):15608-15609.
73. Ray P, Pimenta H, Paulmurugan R, et al. Non-invasive quantitative imaging of protein-protein interactions in living subjects. Proc Natl Acad Sci U S A 2002;99(5):3105-3110.